More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$247.70B
EPS
17.24
P/E ratio
25.7
Price to sales
5.89
Dividend yield
2.201%
Beta
0.433008
Previous close
$462.32
Today's open
$455.52
Day's range
$453.03 - $463.49
52 week range
$312.39 - $483.99
show more
CEO
Robert A. Bradway
Employees
31500
Headquarters
Thousand Oaks, CA
Exchange
Nasdaq Global Select
Shares outstanding
540911490
Issue type
Common Stock
Healthcare
Pharmaceuticals
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Amgen Securities Litigation
SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Amgen Securities Litigation: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE AMGEN INC. SECURITIES LITIGATION Civil Action No. 1:23-cv-02138 (JPC) (HJR) CLASS ACTION SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS THAT PURCHASED OR OTHERWISE ACQUIRED AMGEN INC. (“AMGEN” OR THE “COMPANY”) COMMON STOCK BETWEEN JULY 29, 2020 AND APRI.
Business Wire • 2 hours ago

Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500
Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?
24/7 Wall Street • a day ago

A New King of Dividend ETFs
The Schwab U.S. Dividend Equity ETF (SCHD) is now the largest dividend ETF in the U.S. As of mid-November 2026, the fund held $125 billion in assets under management. It combines rigorous fundamental screening with a low 0.06% expense ratio.
ETF Trends • a day ago

Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness
Dow Jones biotech giant Amgen stock is trading in a buy zone following its recent breakout move amid the ongoing market weakness.
Investors Business Daily • Nov 16, 2026

The Winners Inside SCHD - November 2026
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
Seeking Alpha • Nov 17, 2026

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.
The Motley Fool • Nov 13, 2026

Dividend Champion, Contender, And Challenger Highlights: Week Of November 15
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Seeking Alpha • Nov 13, 2026

Amgen's experimental Sjogren's drug meets late-stage trial goal
Amgen said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease, an autoimmune condition.
Reuters • Nov 11, 2026

Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data
Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.
Investors Business Daily • Nov 11, 2026

Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in which the immune system mistakenly attacks the body's moisture-producing glands.
Benzinga • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amgen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.